
AI-Designed PRMT5 Inhibitor Nominated in UAE
Today marks a historic moment for Insilico and another world's first in AI-powered drug discovery. We nominated the first preclinical/developmental candidate in the UAE. It is also our 30th PCC/DC nominated in the past 5 years. 12 molecules reached clinical stage, 3 Phase 2, 1 Phase 2a complete. But this PCC is very special and demonstrates the true power of AI that leaves no doubt in terms of its impact on drug discovery. We set up a site in the UAE just over 3 years ago and thanks to Abu Dhabi Investment Office مكتب أبوظبي للاستثمار we managed to bring together some of the top AI scientists, computational and medicinal chemists to scale our foundation models and to run drug discovery programs. Today, together with the @EDE_UAE Emirates Drug Establishment مؤسسة الإمارات للدواء we announced the discovery of the first home grown novel highly-CNS penetrant potent PRMT5 inhibitor with excellent preclinical safety profile and combination potential with our CNS-penetrant MAT2A inhibitor. We demonstrated that in the very large region that never discovered a novel drug before, AI enabled the discovery of a drug with a high level of novelty and commercial tractability. It marks a very important milestone in our company history as we can now empower entire nations to get a seat at the high-stakes molecular roulette table where winning means saving millions of lives around the world. It is also a massive milestone in my life as I firmly believe that establishing the vibrant biomedical industry would contribute to the cultural renaissance and achieving peace and prosperity in the Middle East. It is also the region where the leadership may with time allow for faster and more sophisticated human clinical trials which is the biggest bottleneck in AI-powered drug discovery. We urgently need the ability to have human-in-the-loop to provide frontier AI with rapid feedback and allow for scale up and recursive self improvement. This PCC/DC nomination also comes at a time when the UAE demonstrated unprecedented national resilience providing high level of safety to the residents despite unprecedented adversity. Our team at the International Renewable Energy Agency (IRENA) continued working without interruption and delivered this PCC in record time and on budget. Congratulations to the team, to ADIO, to EDE, and DoH and everyone involved. Also, thanks to all my LinkedIn friends for your support and encouragement over the years. Link to the article in the comments
Google's Mac Codex Release Crucial for Future Dominance
If @Google does not release their own version of Codex on Mac in the next 90 days, they will lose the game. If they do, they may become the world's most valuable company

AI-Driven Drug Discovery Beats Billion‑Dollar AI Acquisitions
This is interesting. Just when I thought that Cursor was slaughtered by Claude and Codex, @SpaceX wants to buy them for $60 Billion. For $60 Billion, I can probably make the astronauts more resistant to radiation with potent radioprotectors...

Insilico Tops AI Drug Discovery, Drives Oncology Breakthroughs
I had to skip this year's #AACR2026 but I am watching it from the distance. Our posters and team did a very good job - it looks like our clinical-stage oncology assets are finally being better understood by the pharma...

World's First Longevity Board Launched to Accelerate Aging Therapies
I am very happy to report that we formed the world's first Longevity Board at the public biotechnology company. Our objective is to discover and develop longevity therapeutics with pipeline-in-a-product potential. GLP-1 therapeutics paved the way and demonstrated the path...

AI-Driven Medicine and Cars to Extend Productive Life
Extending human productive life and restoring lost function should be the ultimate objective of AI-powered discovery medicine. It was a great pleasure to share some the story, current progress and long-term plans at one of the most impactful events of...

Biotech Must Prioritize Collaboration, Not Nationalism, for Patients
After a week in Washington DC at one of the best new annual events by @semafor , I came to China for just 2 nights to meet some of my friends from Washington. I even had to skip this year's...

AI-Driven Drug Discovery: Current Landscape and Future Promise
Cool review and perspective on the current state and the future of AI-powered drug discovery https://t.co/AgwqOlt4RU
AI-Optimized Molecules Drive Clinical Interest and Expansion
#AACR2026 is in full swing and our posters are very popular. And some pharma companies realized that we have clinical data now and the molecules were AI-optimized to avoid the common liabilities. Finally, some genuine interest and we will have...

R&D Hype Unchecked: No Accountability for Drug Promises
Nice article by @TClozel in @FastCompany. Link in comments. The funny thing is that every company he mentioned and many others promised many years ago and still promise cheaper, faster, higher PoS drugs and many of them do not...

AI Pharma Success Measured by Speed, Cost, Not Approvals
Very often I am being asked when will the first drugs designed using AI receive regulatory approval. The answer is very simple - there are several drugs that were already approved. For example, the first antibody to receive regulatory approval...
Demanding 1,200 Benchmark Test Before Claiming SOTA
Until they test it in @InSilicoMeds benchmarks (1,200 benchmarks), I will not believe that this is anywhere close to SOTA. Let's benchmark it folks. Whoever has access and would like to benchmark - let's collaborate

Chinese Pharma Leads Speed, Insilico Wins on Novelty
Very insightful article in China Daily. There is a big delta between the AI CRO model and AI Biotech model. At Insilico, we do not compete with Xtalpi or other local companies. The most hardcore competitors now are the large...

AI‑Driven Trials Could Propel India’s Pharma Leaders
One of the most amazing encounters at Semafor World Economy was with Satish Reddy of Dr. @bindureddy's Laboratories , the largest or second largest pharma company in India, depending on how you look at it. Now, they are also looking...

AI-Driven Precision Oncology Breakthrough From Korean Researchers
One unexpected but very insightful paper in Nature BJC from a leading institution in Korea on precision oncology and AI-driven drug discovery. I read it with great pleasure and you should read it too. https://t.co/vpxofjt9Mn https://t.co/SXs4n72CcY